{"description":"Adverse events are collected from the first dose of Mk-3475 or Vorinostat, and are collected through 30 days post the last dose of therapy.","eventGroups":[{"deathsNumAffected":22,"deathsNumAtRisk":25,"description":"MK-3475 combined with vorinostat in HNSCC patients","id":"EG000","otherNumAffected":11,"otherNumAtRisk":25,"seriousNumAffected":1,"seriousNumAtRisk":25,"title":"Head and Neck Squamous Cell Carcinoma"},{"deathsNumAffected":23,"deathsNumAtRisk":25,"description":"MK-3475 combined with vorinostat in SGC patients","id":"EG001","otherNumAffected":19,"otherNumAtRisk":25,"seriousNumAffected":1,"seriousNumAtRisk":25,"title":"Salivary Gland Carcinoma"}],"frequencyThreshold":"0","otherEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Hepatobiliary disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":25,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":25,"numEvents":1}],"term":"alanine amintotransferase (ALT) increased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Hepatobiliary disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":25,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":25,"numEvents":1}],"term":"asparate aminotransferase (AST) increased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":25,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":25,"numEvents":0}],"term":"cough"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Renal and urinary disorders","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":25,"numEvents":2},{"groupId":"EG001","numAffected":5,"numAtRisk":25,"numEvents":6}],"term":"creatinine increased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":25,"numEvents":3},{"groupId":"EG001","numAffected":4,"numAtRisk":25,"numEvents":6}],"term":"Fatigue"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":25,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":25,"numEvents":1}],"term":"Fever with Leukocytosis"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":25,"numEvents":2},{"groupId":"EG001","numAffected":0,"numAtRisk":25,"numEvents":0}],"term":"Hyponatremia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":25,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":25,"numEvents":0}],"term":"Malaise"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":25,"numEvents":1},{"groupId":"EG001","numAffected":3,"numAtRisk":25,"numEvents":4}],"term":"Nausea"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":25,"numEvents":1},{"groupId":"EG001","numAffected":2,"numAtRisk":25,"numEvents":2}],"term":"Vomiting"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":25,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":25,"numEvents":1}],"term":"Neuritis"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Immune system disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":25,"numEvents":1},{"groupId":"EG001","numAffected":1,"numAtRisk":25,"numEvents":1}],"term":"Adrenal insufficiency"}],"seriousEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Endocrine disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":25,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":25,"numEvents":1}],"term":"Adrenal Insufficiency"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":25,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":25,"numEvents":0}],"term":"Pneumonitis"}],"timeFrame":"All-Cause Mortality was monitored for up to 7 years and 6 months; serious and/or other adverse events were assessed up to 3 years and 6 months."}